Search
Selected Filter
Filter Results
Displaying 1–10 of 161 diseases results
-
Oct 25, 2024
Eye on the Cure Podcast | Episode 75: Sharon King
Sharon King, co-founder and president of Taylor’s Tale, talks to host Ben Shaberman about her family’s journey when her daughter Taylor was diagnosed with Batten disease.
-
Oct 23, 2024
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Merger will provide additional capital for gene therapy development.
-
Oct 21, 2024
Share Your Vision: Heather Edwards
Heather Edwards has turned her personal journey with cone-rod dystrophy into a mission to support others facing similar challenges. Despite facing difficulties during her youth, Heather now uses her experiences to advocate for awareness and support for blinding diseases, emphasizing that blindness is a spectrum and each person’s experience is uniquely valuable.
-
Oct 11, 2024
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
Researchers hope the molecule will slow the vision and hearing loss associated with USH3.
-
Oct 7, 2024
Soaring as a Visionary Leader at Southwest
James Ashworth, Vice President of Customer Care at Southwest Airlines, has dedicated his career to the airline industry and his advocacy for the visually impaired, driven by his personal experience with rod-cone dystrophy. His leadership and commitment to supporting the blind and visually impaired community have led to significant contributions, including employment initiatives and technological advancements to aid those with vision loss.
-
Sep 26, 2024
Vision: A Memoir of Blindness and Justice — A New York Times Editor’s Pick
“Tatel’s humility and tenacity shine. The result is a stirring reflection on an extraordinary life,” Publishers Weekly
-
Sep 23, 2024
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
Known as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.
-
Sep 20, 2024
Eye on the Cure Podcast | Episode 73: Dr. Zuhal Butuner
Dr. Zuhal Butuner talks about her company’s two emerging RNA therapies for LCA10 and USH2A.
-
Sep 18, 2024
AAVantgarde Bio’s Dual-Vector USH1B Gene Therapy Moves into Phase 1/2 Clinical Trial
The trial is the first ever for a dual AAV gene therapy delivered to the retina.
-
Sep 17, 2024
The Phase 3 trial is expected to begin in Q1 2025